Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
企業コードAMPH
会社名Amphastar Pharmaceuticals Inc
上場日Jun 25, 2014
最高経営責任者「CEO」Dr. Yongfeng (Jack) Zhang, Ph.D.
従業員数2028
証券種類Ordinary Share
決算期末Jun 25
本社所在地11570 6th St
都市RANCHO CUCAMONGA
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号91730
電話番号19099809484
ウェブサイトhttps://amphastar.com/
企業コードAMPH
上場日Jun 25, 2014
最高経営責任者「CEO」Dr. Yongfeng (Jack) Zhang, Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし